Randomized Comparison of the Effect of 0.2% Glyceryl Trinitrate and 0.5% Topical Nifedipine in Acute Anal Fissure Treatment

© Ozan Akıncı¹, © Sangar M Farooq Abdulrahman², © Özlem Güngör³, © Necip Serdar Yüceyar², © Asiye Perek², © Murat Süphan Ertürk²

¹Hakkari State Hospital, Department of General Surgery, Hakkari, Turkey

²Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of General Surgery, Istanbul, Turkey

³Hakkari State Hospital, Department of Radiology, Hakkari, Turkey

ABSTRACT

Aim: The aim of this prospective clinical trial study is to compare the effect of 0.2% glyceryl trinitrate and 0.5% topical nifedipine on acute anal fissure treatment and recurrence prevention.

Method: The study included a total of 100 patients who were diagnosed with acute anal fissure and randomly separated into two groups, 0.2% glyceryl trinitrate (GTN) group, and 0.5% topical nifedipine (ND) group. At the first visit age, sex, presence of constipation, pain duration after defecation, and visual analog scale (VAS) score were recorded. After the twenty-one days of treatment symptomatic relief levels, healing, VAS score and side effects of drugs were recorded.

Results: The female/male ratio for the GTN group was 50/50%, while it was 54/46% for the ND group. The mean age was 29.3 for the GTN group and 30.7 for the ND group. After treatment, excellent symptomatic relief level in ND group (56%) was higher than GTN group (22%) (p:0.005). Post-treatment mean VAS score was significantly lower in the ND group than the GTN group (p<0.001). The mean decrease of VAS score in the ND group between pre and post-treatment was significantly higher than GTN group (p:0.001). The healing rate in the ND group (86%) was higher than the GTN group (64%) (p:0.011). The drug side effect rate was significantly lower in the ND group (4%) compared to GTN group (22%) (p:0.007). The recurrence rate was 38% in the GTN group, 18% in the ND group (p:0.026).

Conclusion: Our study shows that both glyceryl trinitrate and topical nifedipine have favorable effects on anal fissure treatment. However, topical 0.5% nifedipine is superior to 0.2% glyceryl trinitrate in the treatment of anal fissure in terms of symptomatic relief, decrease in pain score, healing, drug side effects, and recurrence rate.

Keywords: Acute anal fissure, glyceryl trinitrate, nifedipine

Introduction

Anal fissures are painful tears that occur in stratified squamous epithelium of the anal canal. The exact etiology is unclear, however, it's believed that sphincter spasm which occurs due to traumatic injury of hard stool passage, leads to an increase in anal canal pressure and local ischemia of the anal mucosa.^{1,2} The most common symptoms are pain, spasm and rectal bleeding. Acute anal fissures are short-term shallow lesions, while chronic anal fissures are deep and persisting lesions lasting more than 6-8 week.³ The vast majority of the anal fissures are localized in the posterior midline.⁴ The aim of the treatment is to decrease internal anal sphincter resting pressure and to improve blood flow again in the ischemic area. The majority of anal fissures resolve without surgical intervention.

Traditional surgical approaches are anal dilatation and lateral internal sphincterotomy but may result with anal incontinence.⁵ In addition to this important complication, the workload and cost of surgical intervention lead to searching alternative management methods. Recent literature analysis acknowledges that medical treatment should be the first-line of therapy, and surgical treatment should be planned in case of recurrence and medical treatment failure.⁶ Agents such as glyceryl trinitrate, diltiazem, nifedipine, botulinum toxin, bethanechol, and indoramin are among chemical sphincterotomy options.⁷ There is still debate on which medical agent is superior in anal fissure healing and recurrence prevention. Glyceryl trinitrate, a nitric oxide donor, has been shown by multiple studies to be effective in the treatment of

anal fissure by lowering anal sphincter resting pressure.^{6,8,9} Nifedipine which is a calcium channel blocker decreases anal sphincter tone through blocking voltage-gated and non-voltage-gated adrenergic receptor-operated calcium channels in smooth muscle membrane of vessels.¹⁰

The aim of this study is to compare the effect of 0.2% glyceryl trinitrate and 0.5% topical nifedipine on acute anal fissure treatment and recurrence prevention.

Materials and Methods

This prospective study included a total of 100 patients who were diagnosed with acute anal fissure at Hakkari State Hospital General Surgery Clinic between April 2019 and February 2020. Approval has been obtained from local ethics committee for the study (approval no: 02/20.11.2019). The patients were informed in detail about the study and written consents were obtained. Patients over 18 years of age diagnosed with an acute anal fissure for the first time were included in the study. Patients with chronic anal fissure, inflammatory bowel disease, hemorrhoid, tuberculosis, anal cancer, history of anal surgery, pregnant and lactating, under the age of 18 and patients who didn't want to enroll in the study were excluded.

Patients were randomly separated into two groups, 0.2% glyceryl trinitrate (GTN) group, and 0.5% topical nifedipine (ND) group. At the first visit age, sex, presence of constipation, difficulty in defecation, pain duration after defecation, amount of fluid consumed daily, anatomic localization of the fissure and visual analog scale (VAS) score ranging from 0 to 10 for pain assessment were recorded. Roma-4 criteria was used as a reference for diagnosis of constipation.¹¹ **While questioning the daily fluid consumption amounts of the patients, 0.5-1.0-1.5-2.0-2.5-3.0-3.5-4.0 liter options are presented to them and the approximate amount of fluid consumed by the patients is recorded in this way.** 0.2% glyceryl trinitrate was applied to the GTN group and 0.5% topical nifedipine to the ND group twice daily for twenty-one days. Patients were informed to apply the ointment as much as chickpea grain around the anus and 1 cm within the anal canal. 0.2% glyceryl trinitrate and 0.5% nifedipine ointments were prepared by a pharmacist because neither of the ointments is available by their trade names in Turkey. Powder forms of 0.5 grams nifedipine capsule active ingredient and 0.2 grams of glyceryl trinitrate were mixed with 100 grams of petroleum jelly and placed in 100-gram ointment boxes. **Ointments were obtained from the pharmacy with a magistral prescription.** All patients of both groups were prescribed stool softeners and informed to consume a fiber-rich diet. **All patients were advised usage of warm sitz bath for 10-15 minutes, 2-3 times daily.** No analgesics were prescribed.

Patients were assessed after twenty-one days of treatment. In this second assessment, symptomatic relief levels, healing, VAS scores after treatment and side effects of drugs (such as headache, perineal irritation) were recorded. Symptomatic relief levels were assessed in a 4 level model as "excellent, good, moderate and nil". Patients who were found to have fissure again in the control examination were given additional therapy with the same drug and dosage for two more weeks. **Rectoscopy was done for all of the patients after symptomatic relief and other pathologies were ruled out. None of the patients had undergone rectoscopy before treatment.** All cases were re-examined for recurrence three months after treatment.

Statistical Analysis

The statistical analysis of the findings obtained from the study was performed with the SPSS version 17.0 program. Suitability of variables to normal distribution was assessed by histogram graphics and Kolmogorov-Smirnov test. While presenting descriptive analyzes, mean, standard deviation and median values were used. Pearson chi-square and Fischer's exact tests were used in 2x2 tables. Mann-Whitney U test was used for the evaluation of not normally distributed (non-parametric) variables between groups. A p-value of <0.05 was considered statistically significant.

Results

There were 50 patients in each group, the female/male ratio for the GTN group was 25/25 (50/50%), while it was 27/23 (54/46%) for the ND group. The mean age was 29.3 for the GTN group and 30.7 for the ND group. There was no statistically significant difference between the groups in terms of age and sex distribution (Table 1).

When the symptoms of the patients were evaluated in both groups, the most common symptom was pain (100%), then bleeding, and itching respectively (Table 2). Constipation was seen in 62% of GTN group patients, and 68% of the ND group. 12 (24%) patients in the GTN group and 14 (28%) in the ND group reported that they always had difficult defecation. The average pain duration after defecation was observed to be 3.25 hours for the GTN group and 3.30 hours for the ND group. When daily fluid consumption was questioned, it was found that those in the GTN group consumed 1.55 liters/day and those in the ND group consumed 1.57 liters/day (Table 3). Fissures were found to be located in the posterior midline in 70% of the GTN group and 74% of the ND group. There was no statistically significant difference between the two groups in terms of symptoms, constipation, frequency of difficult defecation, pain duration after defecation, daily fluid consumption, and localization of the fissure (Table 2,3).

When the patients were seen and examined after 21 days of treatment the proportion of patients with excellent symptomatic relief in the ND group was 56% and 22% in the GTN group. While the good and moderate symptomatic relief rates in the ND group were 24% and 14%, respectively, these rates were 50% and 22% in the GTN group. Excellent symptomatic relief was significantly higher in ND group than in GTN group ($p:0.005$) (Table 4). No significant difference was seen between the groups when the pre-treatment mean VAS score was evaluated ($p:0.273$). Post-treatment mean VAS score was significantly lower in the ND group than the GTN group ($p<0.001$). The mean decrease of VAS score in the ND group between pre and post-treatment was 6.14 ± 2.07 , while it was 5.02 ± 1.92 in the GTN group and the decrease of VAS score in ND group was significantly higher than GTN group ($p:0.001$) (Table 4).

When the patients were seen and examined after 21 days

of treatment, the healing rate in the ND group (86%) was higher than the GTN group (64%) ($p:0.011$). Headache was seen in 11(22%) patients of the GTN group, 2(4%) patients in the ND group experienced local irritation. **None of the patients interrupted the treatment due to the side effects of the drugs.** The drug side effect rate was significantly lower in the ND group compared to GTN group ($p:0.007$). Evaluation after 3 months of follow-up showed that the recurrence rate was 38% in the GTN group, 18% in the ND group, and the recurrence rate in the ND group was statistically significantly lower ($p:0.026$).

Discussion

An anal fissure is one of the most commonly seen anorectal diseases. Clinically the development of fissure is almost always due to chronic constipation or following passage of hard/difficult stool. The posterior midline is known to be

Table 1. Demographic characteristics of the patients participating in the study according to the groups.

		GTN		ND		Total		P
		n	%	n	%	n	%	
Gender	Male	25	(50.00)	27	(54.00)	52	(52.00)	0.689 ¹
	Female	25	(50.00)	23	(46.00)	48	(48.00)	
Age		29.36 $\pm$ 8.97	27.00	30.78 $\pm$ 8.55	29.00	30.07 $\pm$ 8.75	28.00	0.288 ²

¹Chi-square Test, ²Mann-Whitney U Test

Table 2. Comparison of the symptoms, constipation, difficulty in defecation and fissure localization of the patients at the first presentation between the groups

		GTN		ND		P
		n	%	n	%	
Pain	No	0	(.00)	0	(.00)	***
	Yes	50	(100.00)	50	(100.00)	
Bleeding	No	17	(34.00)	20	(40.00)	0.534
	Yes	33	(66.00)	30	(60.00)	
Itching	No	38	(76.00)	37	(74.00)	0.817
	Yes	12	(24.00)	13	(26.00)	
Constipation	No	19	(38.00)	16	(32.00)	0.529
	Yes	31	(62.00)	34	(68.00)	
Difficulty in defecation	Never	1	(2.00)	2	(4.00)	0.889
	Sometimes	18	(36.00)	16	(32.00)	
	Often	19	(38.00)	18	(36.00)	
	Always	12	(24.00)	14	(28.00)	
Location	Anterior midline	15	(30.00)	13	(26.00)	0.656
	Posterior midline	35	(70.00)	37	(74.00)	

Chi-square Test

more susceptible to trauma and to be torn first due to the anorectal angle and topography of the pelvic floor muscles.³ In the light of anal manometry, arteriography, and doppler findings, internal anal sphincter hypertonicity, and relative poor perfusion are believed to be two main factors in the pathogenesis of anal fissure.^{12,13,14} Klosterhalfen et al. showed that posterior commissure, where 90% of anal fissures are localized, is less perfused than the other parts of the anal

Graphic 1: Comparison of symptomatic relief levels of patients at the end of treatment between the groups

canal in postmortem angiographies.¹⁵ For this reason, typically anal fissures are often located in the posterior midline. In the literature, it has been reported that anal fissures are located in the posterior midline at a rate of 70.5 - 94%.^{16,17,18} In 72% of the patients in our study, the fissure was located in the posterior midline, while in 28% in anterior midline. Atypical fissures are multiple, localized outside the midline, and develop secondary to diseases such as AIDS, crohn, malignancy, and tuberculosis. Patients with atypical fissures were not included in our study.

Due to surgery-related anal incontinence and other complications, there is a tendency in today's medicine from surgery towards medical modalities in the treatment of anal fissures.¹⁹ Chemical sphincterotomy is preferred as the first-line of treatment since it is non-invasive, does not require anesthesia, reversible, repeatable, applicable at home, economic, and practical.^{20,21} Topical GTN is the most widely used chemical agent in the treatment of anal fissures, it reduces anal sphincter tonicity by its non-adrenergic, non-cholinergic effect and its main side effect is headache

Table 3. Comparison of the pain duration after defecation and amount of fluid consumed daily between the groups.

	GTN			ND			P
	Mean	S.D.	Median	Mean	S.D.	Median	
Pain duration after defecation (hour)	3.25	±2.47	2.00	3.30	±2.44	2.50	0.967
Amount of fluid consumed daily (liter)	1.57	±.83	1.25	1.55	±.80	1.50	0.928

Mann-Whitney U test, SD: standard deviation

Table 4. Comparison of clinical characteristics of the groups after treatment

		GTN		ND		p
		n	%	n	%	
Symptomatic relief level	Nil	3	(6.00)	3	(6.00)	0.005^a
	Moderate	11	(22.00)	7	(14.00)	
	Good	25	(50.00)	12	(24.00)	
	Excellent	11	(22.00)	28	(56.00)	
Healing (21 days)	No	18	(36.00)	7	(14.00)	0.011^a
	Yes	32	(64.00)	43	(86.00)	
Drug side effects	No	39	(78.00)	48	(96.00)	0.007^a
	Yes	11	(22.00)	2	(4.00)	
Recurrence (3 months)	No	31	(62.00)	41	(82.00)	0.026^a
	Yes	19	(38.00)	9	(18.00)	
Pre-treatment VAS score*		7.94±1.46		7.68±1.28		0.273 ^b
Post-treatment VAS score*		2.92±1.75		1.54±1.43		<0.001^b
Decrease of VAS score*		5.02±1.92		6.14±2.07		0.001^b

^aChi-square Test, ^bMann Whitney U Test.

*mean ± standard deviation

which occurs in 40% of the patients.²² Besides, it also has side effects like tachyphylaxis, orthostatic hypotension, and syncope.²³ The high recurrence rate is another disadvantage of GTN.^{23,24} **It has been reported that there is no significant difference between 0.4% and 0.2% GTN forms in terms of healing of anal fissure, and 0.4% GTN has a higher rate of headache.**^{25,26} For these reasons, we preferred the 0.2% GTN form in our study.

Calcium channel blockers like nifedipine and diltiazem are successful agents in the treatment of anal fissures in both oral and topical application.^{7,10,22} It has been shown that topical application of nifedipine has fewer side effects and a higher healing rate compared to oral administration.^{16,27,28} The transport of calcium through L-type calcium channel is essential in maintaining internal anal sphincter tone, and nifedipine breaks the fissure cascade by reducing spontaneous sphincter activity through preventing intracellular access of calcium.²⁹ Experimental studies have shown that nifedipine has also a local anti-inflammatory and a favorable effect on microcirculation.^{30,31}

A significant decrease in the VAS score and symptomatic relief was observed in both GTN and ND group patients in our study. However, when the decrease in the VAS score rate and symptomatic relief levels were compared between the two groups, nifedipine was observed to be significantly more effective. Besides, the rate of healing in anal fissure was higher in the ND group (86% versus 64%) when an anal examination was done after treatment. The healing rate in anal fissure was reported to be 94% by Perrotti et al. and 85% by Katsinelos et al. when nifedipine was used.^{7,32} Similar to our study, Shrestha et al. also showed that topical ND has a higher healing rate than GTN.²¹ In another study, it was reported that both drugs lead to a significant decrease in pain scores with no difference between the groups, but the healing rate was higher in the ND group than the GTN group.³³

When drug side effects were examined in our study, it was significantly higher in GTN group than ND group ($p:0.007$). This ratio was 40% vs 5% and 16% vs 7% in the studies of Erzi et al. and Shrestha et al., respectively, and both studies have shown that the side effects of the GTN group were significantly higher.^{21,33} Headache; the most important side effect of GTN reduces drug compliance and prevents the patients from taking the drug regularly and for the expected duration. For this reason, we can say that ND is more advantageous than GTN concerning both patient satisfaction and tolerance.

After chemical sphincterotomy treatment, anal canal pressure returns to pre-treatment levels and from this aspect, chemical sphincterotomy differs from surgical sphincterotomy. For this reason, chemical sphincterotomy has a higher risk of recurrence. In our study, the recurrence

rate of the ND group was significantly lower than that of the GTN group (18% vs 38%) ($p:0.026$). Shrestha et al. reported similar results in their study, while two other studies reported no difference between the two drugs in terms of recurrence.^{21,33,34}

The limitations of our study were its small number of patients, being single-centered, short follow-up period (3 months), and inability to measure anal canal resting pressure before and after treatment in the institution where the study was done.

Conclusion

Data obtained from our study shows that both glyceryl trinitrate and topical nifedipine have favorable effects on anal fissure treatment. However, topical 0.5% nifedipine is superior to 0.2% glyceryl trinitrate in the treatment of anal fissure in terms of symptomatic relief, decrease in pain score, healing, drug side effects, and recurrence. But, it is a fact that there is a need for prospective clinical studies with a larger number of patients, long-term follow-up, and that are supported with manometric measurements.

Ethics

Ethics Committee Approval: This study was approved by Van Yüzüncü Yıl University, Clinical Trials Ethics Committee.

Informed Consent: A written informed consent concerning the risks of study was obtained from all patients.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Jonas M, Scholefield JH. Anal Fissure. *Gastroenterol Clin North Am* 2001;30:167-181.
2. Schouten WR, Briel JW, Auwerda JJ. Relationship between anal pressure and anodermal blood flow. The vascular pathogenesis of anal fissures. *Dis Colon Rectum* 1994;37:664-669.
3. Menteş B, Leventoglu S. Anal fissür. In: Menteş B, Bulut T, Alabaz O, Leventoglu S, eds. *Anorektal Bölgenin Selim Hastalıkları*. TSCRS Society, Ankara. 2011:37-47.
4. Dunn KMB, Rothenberg DA. Colon, Rectum and Anus. In: Brunicaudi FC, eds. *Schwartz's Principles of Surgery*. USA, 10th edition. 2014:1175-1239.
5. Pernikoff BJ, Eisenstat TE, Rubin RJ, Oliver GC, Salvati EP. Reappraisal of partial lateral internal sphincterotomy. *Dis Colon Rectum* 1994;37:1291-1295.
6. Suvarna R, Hanumanthappa MB, Panchami Rai DG. Topical diltiazem versus topical glyceryl trinitrate (GTN) in the treatment of chronic anal fissure: prospective study. *Int J Biol Med Res* 2012;3:1747-1750.
7. Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Chatzimavroudis G, Zavos C, Katsinelos T, Papaziogas B. Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity. *World J Gastroenterol* 2006;12:6203-6206.

8. Bacher H, Mischinger HJ, Workgartner G, Cerweika H, Shabrawi AE, Pfeifer J, Schweiger W. Local Nitroglycerin for treatment of anal fissures: An alternative to Lateral Sphincterotomy. *Dis Colon Rectum* 1997;40:840-845.
9. Nelson RA. Systematic review of medical therapy for anal fissure. *Dis Colon Rectum* 2004;47:422-431.
10. Cook TA, Humphreys S, McC Mortensen NJ. Oral Nifedipine Reduces Resting Anal Pressure and Heals Chronic Anal fissure. *Br J Surg.* 1999;86:1269-1273.
11. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. *Gastroenterology.* 2016;150:1257-1261.
12. Schouten WR, Briel JW, Aurwerda JJ, De Graaf EJ. Ischaemic nature of anal fissure. *Br J Surg.* 1996;83:63-65.
13. Utzig MJ, Kroesen AJ, Buhr HJ. Concepts in pathogenesis and treatment of chronic anal fissure: a review of the literature. *J Gastroenterol.* 2003;98:968-974.
14. Lund JN, Scholefield JH. Aetiology and treatment of anal fissure. *Br J Surg* 1996;83:1335-1344.
15. Klosterhalfan B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: A possible cause of chronic, primary anal fissure. *Dis Colon Rectum* 1989;32:43-52.
16. Golfam F, Golfam P, Golfam B, Pahlevani P. Comparison of Topical Nifedipine With Oral Nifedipine for Treatment of Anal Fissure: A Randomized Controlled Trial. *Iran Red Crescent Med J.* 2014;16: e13592.
17. Hananel N, Gordon PH. Re-examination of clinical manifestations and response to therapy of fissure-in-ano. *Dis Colon Rectum* 1997;40:229-233.
18. Tauro LF, Shindhe VV, Aithala PS, Martis JJ, Shenoy HD. Comparative Study of Glyceryl Trinitrate Ointment Versus Surgical Management of Chronic Anal Fissure. *Indian J Surg* 2011;73:268-277.
19. Sanei B, Mahmoodieh M, Masoudpour H. Comparison of topical glyceryl trinitrate with diltiazem ointment for the treatment of chronic anal fissure: a randomized clinical trial. *Acta Chir Belg* 2009;109:727-730.
20. Khan MS, Akbar I, Zeb J, Ahmad S, Khan A. Outcome of 0.2% Glyceryltrinitrate Cream Versus 2% Diltiazem Cream In The Treatment Of Chronic Anal Fissure. *J Ayub Med Coll Abbottabad* 2017;29:280-284.
21. Shrestha SK, Thapa PB, Maharjan DK, Tamang TY. Effectiveness of 0.2% Glyceryl Trinitrate and 0.5% Nifedipine in the Treatment of Chronic Anal Fissure. *JNMA J Nepal Med Assoc.* 2017;56:149-152.
22. Golfam F, Golfam P, Khalaj A, Mortaz SSS. The Effect of Topical Nifedipine in Treatment of Chronic Anal Fissure. *Acta Medica Iranica* 2010;48:295-299.
23. Carapeti EA, Kamm MA, McDonald PJ, Chadwick SJ, Melville D, Phillips RK. Randomized controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate. *Gut* 1999;44:727-730.
24. Evans J, Luck A, Hewett P. Glyceryl trinitrate vs. lateral sphincterotomy for chronic anal fissure: prospective randomized trial. *Dis Colon Rectum* 2001;44:93-97.
25. Scholefield JH, Bock JU, Marla B, Richter HJ, Athanasiadis S, Pröls M, et al. A dose finding study with 0.1%, 0.2%, and 0.4% glyceryl trinitrate ointment in patients with chronic anal fissures. *Gut.* 2003;52: 264-269.
26. Bailey HR, Beck DE, Billingham RP, Binderow SR, Gottesman L, Hull TL, et al. A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures. *Dis Colon Rectum.* 2002;45:1192-1199.
27. Jonas M, Neal KR, Abercrombie JF, Scholefield JH. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. *Dis Colon Rectum.* 2001;44:1074-1078.
28. Sahebally SM, Ahmed K, Cerneveciute R, Iqbal A, Walsh SR, Joyce MR. Oral versus topical calcium channel blockers for chronic anal fissure-a systematic review and meta-analysis of randomized controlled trials. *Int J Surg* 2017;44:87-93.
29. Cook TA, Brading AF, Mortensen NJ. Effects of Nifedipine on Anorectal smooth muscle in vitro. *Dis Colon Rectum* 1999;42:782-787.
30. Oshiro H, Kobayashi I, Kim D, Takenaka H, Hobson RW 2nd, Duran WN. L-type calcium channel blockers modulate the microvascular hyperpermeability induced by platelet-activating factor in vivo. *J Vasc Surg* 1995;22:732-739.
31. Fleischmann JD, Huntley HN, Shingleton WB, Wentworth DB. Clinical and Immunological response to nifedipine for the treatment of interstitial cystitis. *J Urol* 1991;146:1235-1239.
32. Perrotti P, Bove A, Antropoli C, Molino D, Antropoli M, Balzano A, De Stefano G, Attena F. Topical nifedipine with lidocaine ointment vs. active control for treatment of chronic anal fissure: results of a prospective, randomized, double-blind study. *Dis Colon Rectum.* 2002;45:1468-1475.
33. Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. *Dis Colon Rectum.* 2003;46:805-808.
34. Mustafa NA, Cengiz S, Türkyılmaz S, Yücel Y. Comparison of topical glyceryl trinitrate ointment and oral nifedipine in the treatment of chronic anal fissure. *Acta Chir Belg.* 2006;106:55-58.